One To Watch

Pantherna

Company Overview

A German mRNA-LNP delivery specialist acquired by Munich-based CAR-T developer T-CURX in June 2026, folding its PTXmRNA and PTX-delta-LNP platforms into what is claimed to be the first European biotech to combine proprietary CAR-T and LNP technologies under one roof. Pantherna now operates as a wholly owned subsidiary of T-CURX, with its mRNA engineering and lipid nanoparticle delivery capabilities reoriented toward non-viral in vivo CAR-T cell therapy. The acquisition marks a strategic pivot: what was a platform-agnostic mRNA-LNP company is now embedded within an oncology and cell therapy context, though T-CURX has signaled intent to push in vivo CAR-T beyond oncology as well.

Headquarters and Global Presence

Pantherna Therapeutics is headquartered in Berlin, Germany, and now operates within the T-CURX group, which is based in Munich. As a subsidiary, its LNP research and manufacturing capabilities feed directly into T-CURX's broader clinical translation infrastructure.

Founding and History

Pantherna Therapeutics was founded as an mRNA-LNP platform company in Germany, building proprietary delivery technologies for therapeutic nucleic acid applications. Ansgar Santel was appointed CEO in 2024, steering the company through a partnership with Astellas Pharma on mRNA-based regenerative medicine before the T-CURX acquisition. T-CURX, which closed a USD 20.5 million Series A at the end of 2025, acquired Pantherna on June 1, 2026, with High-Tech Gruenderfonds and existing private investors entering T-CURX's shareholder register as part of the deal.

Therapy Areas and Focus

Under its independent operation, Pantherna targeted respiratory disease and regenerative medicine — PAN-004, its lead program, was an mRNA-LNP Tie2 agonist designed for acute respiratory distress syndrome, an indication with high unmet need and no approved pharmacological standard of care. The Astellas partnership, announced in June 2024 and subsequently expanded, explored direct reprogramming via mRNA for regenerative applications — a more nascent therapeutic category. Post-acquisition, Pantherna's platforms are being redeployed against oncology targets through T-CURX's non-viral in vivo CAR-T programs, with T-CURX also pursuing indications beyond cancer.

Technology Platforms and Modalities

Pantherna's two core proprietary platforms are PTXmRNA, its engineered messenger RNA technology, and PTX-delta-LNP, a lipid nanoparticle delivery system designed for tissue-selective in vivo delivery. The PTX-delta-LNP platform is the strategically valuable asset in the T-CURX context: delivering CAR-encoding mRNA directly into T cells in vivo removes the need for ex vivo cell manufacturing, potentially making CAR-T therapy simpler, faster, and more scalable. Non-viral delivery also sidesteps the safety and manufacturing constraints associated with viral vector-based gene editing approaches.

Key Pipeline and Programs

PAN-004 was Pantherna's most advanced independent program: an mRNA-LNP formulation encoding a Tie2 agonist, intended to restore vascular barrier integrity in ARDS patients. Tie2 is a receptor tyrosine kinase expressed on vascular endothelium whose activation stabilizes capillary junctions — a mechanistically rational target in a condition defined by diffuse alveolar damage and vascular leak. The program's pre-acquisition clinical stage has not been publicly confirmed, but it represented the company's primary demonstration of selective organ-targeting LNP delivery. Under T-CURX, the PTX-delta-LNP system is being applied to deliver CAR-encoding mRNA to circulating T cells in vivo — a pipeline that is moving toward clinical translation supported by the USD 20.5 million Series A capital raised by T-CURX in late 2025. The combined entity describes its in vivo CAR-T approach as targeting both oncology and potentially non-oncology indications, though specific candidate designations beyond the platform level have not been disclosed.

Recent Developments

T-CURX announced the acquisition of Pantherna on June 1, 2026, describing the combined company as the first in Europe to hold both proprietary CAR-T and LNP delivery technologies in-house. Astellas Pharma had expanded its research collaboration with Pantherna in June 2024, initially to evaluate mRNA-based direct reprogramming for regenerative medicine — a deal that raised Pantherna's profile in the partnering market ahead of the T-CURX transaction. Financial terms of the acquisition were not disclosed; T-CURX's pre-existing Series A of USD 20.5 million, closed in late 2025, is the stated funding base for advancing the combined pipeline toward clinical trials.

Key Personnel

Ansgar Santel serves as CEO of Pantherna Therapeutics, appointed to the role in 2024. Santel led the company through the Astellas partnership and into the T-CURX transaction. Specific executive details for T-CURX leadership overseeing the combined entity have not been publicly disclosed at the subsidiary level.

Strategic Partnerships

Astellas Pharma entered a technology evaluation agreement with Pantherna in June 2024, later expanded, covering mRNA-based regenerative medicine via direct cellular reprogramming — a deal that validated the PTXmRNA platform beyond its ARDS application. The T-CURX acquisition, completed June 2026, is the dominant strategic development: High-Tech Gruenderfonds, a prominent German deep-tech seed fund, joined the T-CURX shareholder register as part of the transaction, providing both capital backing and network access for clinical development.

FAQ Section

Full ownership of Pantherna's PTXmRNA and PTX-delta-LNP platforms gives T-CURX direct control over the delivery layer that is arguably the main technical bottleneck in non-viral in vivo CAR-T development. Licensing would have left a critical dependency outside the company; integrating Pantherna as a wholly owned subsidiary makes T-CURX self-sufficient from mRNA engineering through to LNP formulation, which is a distinct competitive position in European cell therapy. High-Tech Gruenderfonds and existing Pantherna investors converting into T-CURX shareholders also suggests the deal was structured as much around aligning incentives as about asset transfer.

Tie2 is a receptor tyrosine kinase expressed on vascular endothelium; its activation by angiopoietin-1 stabilizes the capillary barrier by suppressing inflammatory signaling and reducing vascular permeability. In ARDS, diffuse alveolar flooding caused by capillary leak is the central pathology, making Tie2 agonism a mechanistically direct intervention rather than a broad anti-inflammatory approach. PAN-004 delivered a Tie2 agonist via mRNA-LNP, allowing transient, locally expressed protein without the pharmacokinetic liabilities of recombinant protein administration — an approach that could be controlled in dose and duration in a way that systemic biologics cannot.

Conventional CAR-T requires extracting a patient's T cells, engineering them ex vivo using viral vectors, expanding them in culture, and reinfusing — a process taking weeks, costing hundreds of thousands of dollars per patient, and subject to manufacturing failure. Non-viral in vivo CAR-T instead delivers CAR-encoding mRNA via LNPs directly into circulating T cells in the patient's body, bypassing ex vivo manufacturing entirely. The mRNA approach also produces transient CAR expression rather than permanent genomic integration, which may reduce long-term toxicity risk — a meaningful safety argument at a time when the CAR-T field is under scrutiny for secondary malignancies linked to viral integration.

PAN-004 was Pantherna's lead independent asset: an mRNA-LNP formulation encoding a Tie2 receptor agonist, targeting vascular barrier dysfunction in acute respiratory distress syndrome. The program demonstrated Pantherna's ability to engineer organ-selective LNP delivery — a technically demanding requirement when targeting pulmonary endothelium. Its precise clinical stage at acquisition was not publicly confirmed, but it served as the primary proof-of-concept vehicle for the PTX-delta-LNP platform's tissue-targeting capabilities, making it scientifically relevant even as the commercial focus shifts toward CAR-T under T-CURX.

Prior to the acquisition, Pantherna spanned respiratory disease (PAN-004 in ARDS) and regenerative medicine (the Astellas collaboration on mRNA-driven direct reprogramming), reflecting a platform-first strategy that was deliberately indication-agnostic. Under T-CURX, the primary focus is in vivo CAR-T, initially in oncology, but T-CURX has explicitly flagged intent to extend the modality beyond cancer — autoimmune disease is the most commonly cited non-oncology application for CAR-T broadly. The PTXmRNA and PTX-delta-LNP platforms are versatile enough to underpin programs across these areas.

T-CURX raised a USD 20.5 million Series A at the end of 2025, and the Pantherna acquisition in June 2026 was framed specifically around accelerating "clinical translation" — suggesting the combined entity is in late preclinical or IND-enabling stage for its lead in vivo CAR-T program. The Series A quantum is consistent with a company 12-24 months from a first-in-human study rather than one already generating clinical data. The next material milestone for the combined group is expected to be an IND or CTA filing enabling Phase I trials in an oncology indication.

The key watchpoints for the combined entity are:

Want to Update your Company's Profile?